Dice’s IPO roll comes up with $204M for R&D of oral drugs to rival biologics September 16, 2021 Auto Bot autoimmune diseases, BioPharma, biopharma nl, biotech IPO, Clinical Trials, immunology, investing, Medical Devices, Pharma, South San Francisco 0 Dice Therapeutics raised $204 million from its IPO to support development of oral drugs that could compete against biologic drugs that are injected or infused. Also debuting on the public markets were Tyra Biosciences and Procept BioRobotics.